Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Attention Deficit Hyperactivity Disorder (ADHD) Overview
- Therapeutics Development
- Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview
- Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis
- Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies
- Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies
- Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes
- Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
- Alcobra Ltd
- Amarantus Bioscience Holdings, Inc.
- Arbor Pharmaceuticals, LLC.
- Cerecor Inc.
- Collegium Pharmaceutical, Inc.
- Curemark, LLC
- DURECT Corporation
- Eli Lilly and Company
- H. Lundbeck A/S
- Hisamitsu Pharmaceutical Co., Inc.
- Integrative Research Laboratories Sweden AB
- Intra-Cellular Therapies, Inc.
- KemPharm, Inc.
- Merck & Co., Inc.
- Mnemosyne Pharmaceuticals, Inc.
- Neos Therapeutics, Inc.
- NeuroDerm Ltd.
- Otsuka Holdings Co., Ltd.
- P2D Bioscience
- Polleo Pharma Limited
- Reviva Pharmaceuticals Inc.
- Samyang Biopharmaceuticals Corporation
- Shire Plc
- Signature Therapeutics, Inc
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Tris Pharma, Inc.
- Vernalis Plc
- Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (nicotine + opipramol hydrochloride) - Drug Profile
- amfetamine XR - Drug Profile
- AR-08 - Drug Profile
- BLI-1008 - Drug Profile
- BNC-375 - Drug Profile
- brexpiprazole - Drug Profile
- centanafadine IR - Drug Profile
- centanafadine SR - Drug Profile
- CM-4612 - Drug Profile
- CTX-1301 - Drug Profile
- CTX-1302 - Drug Profile
- dasotraline - Drug Profile
- dextroamphetamine - Drug Profile
- dextroamphetamine MR - Drug Profile
- Drug for Attention Deficit Hyperactivity Disorder - Drug Profile
- edivoxetine - Drug Profile
- eltoprazine - Drug Profile
- etiguanfacine - Drug Profile
- guanfacine hydrochloride ER - Drug Profile
- HTL-1071 - Drug Profile
- IRL-752 - Drug Profile
- ITI-214 - Drug Profile
- KP-415 CR - Drug Profile
- lisdexamfetamine dimesylate - Drug Profile
- Metadoxine ER - Drug Profile
- methylphenidate - Drug Profile
- methylphenidate hydrochloride - Drug Profile
- methylphenidate hydrochloride - Drug Profile
- methylphenidate hydrochloride SR - Drug Profile
- methylphenidate hydrochloride XR - Drug Profile
- MGS-0028 - Drug Profile
- molindone hydrochloride ER - Drug Profile
- PBF-509 - Drug Profile
- PD-2005 - Drug Profile
- PD-2007 - Drug Profile
- PFR-08001 - Drug Profile
- PFR-8026 - Drug Profile
- RP-5063 - Drug Profile
- SHP-465 - Drug Profile
- Small Molecule for ADHD - Drug Profile
- Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile
- Small Molecules to Agonize NMDA2D for ADHD - Drug Profile
- Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimer's Disease - Drug Profile
- Small Molecules to Inhibit COMT for Cognitive Disorders - Drug Profile
- Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
- Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile
- Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile
- TAK-137 - Drug Profile
- TRI-102 - Drug Profile
- V-81444 - Drug Profile
- viloxazine hydrochloride - Drug Profile
- vortioxetine hydrobromide - Drug Profile
- Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
- Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
- Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015
- Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Development by Companies, H1 2015 (Contd..1)
- Number of Products under Development by Companies, H1 2015 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Late Stage Development, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Comparative Analysis by Unknown Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Development by Companies, H1 2015 (Contd..1)
- Products under Development by Companies, H1 2015 (Contd..2)
- Products under Development by Companies, H1 2015 (Contd..3)
- Products under Investigation by Universities/Institutes, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cerecor Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Samyang Biopharmaceuticals Corporation, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Signature Therapeutics, Inc, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma, Inc., H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis Plc, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Assessment by Combination Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H1 2015
- Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2015
- List of Figures
- Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015
- Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Late Stage Development, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Products, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015
- Number of Products by Stage and Top 10 Molecule Types, H1 2015